Novagali withdraws drug marketing application
Novagali Pharma SA has withdrawn the EMEA centralized marketing authorization application for Vekacia (cyclosporin) 0.05% eye drops, which had been intended for the treatment of vernal keratoconjunctivitis (VKC).
Novagali Pharma SA has withdrawn the EMEA centralized marketing authorization application for Vekacia (cyclosporin) 0.05% eye drops, which had been intended for the treatment of vernal keratoconjunctivitis (VKC).
The Committee for Medicinal Products for Human Use (CHMP) had concluded that Vekacia's benefit:risk profile was not positive, and had been investigating the drug.
Novagali had originally submitted the Vekacia marketing authorization application on 27 July 2007.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
